Malaria vaccines should be developed for endemic areas and for travelers, IoM report suggests.
Executive Summary
MALARIA VACCINES: TWO TYPES SHOULD BE DEVELOPED, IoM SUGGESTS in a July 23 report on measures to bring the parasitic disease in check. The first vaccine is "needed to provide long-term protection against disease and to reduce mortality among children in endemic areas of the world," the Institute of Medicine report states. The second vaccine is "needed to induce shorter-term, but highly protective, immunity in non-immune adult travelers entering highly malarious (endemic) areas."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth